New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 10, 2013
15:17 EDTDRTXDurata presents Phase 3 clinical results, in vitro data on dalbavancin
Durata Therapeutics presented clinical trial results from its two Phase 3 DISCOVER 1 and 2 studies and new in vitro data of dalbavancin, further characterizing the effect of the investigational treatment against Gram-positive bacteria. In the two randomized, double-blind clinical studies, dalbavancin was shown to be non-inferior to the comparator regimen, vancomycin with an option to switch to oral linezolid, in treating acute bacterial skin and skin structure infections. In both studies, dalbavancin met its primary and secondary endpoints. Further, recipients in the dalbavancin arms of the studies had fewer treatment emergent adverse events than those in the comparator arms. The in vitro data showed activity against Staphylococcus aureus strains, including methicillin-resistant strains, recovered from patients with osteomyelitis-related wounds. The data were presented in three separate posters at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, or ICAAC.
News For DRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for DRTX

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use